Engineered antibody fragments with infinite affinity as reporter genes for PET imaging

Liu H. Wei, Tove Olafsen, Caius Radu, Isabel J. Hildebrandt, Mark R. McCoy, Michael E. Phelps, Claude Meares, Anna M. Wu, Johannes Czernin, Wolfgang A. Weber

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Reporter gene imaging has great potential for many clinical applications including the tracking of transplanted cells and monitoring of gene therapy. However, currently available reporter gene-reporter probe combinations have significant limitations with the biodistribution of the reporter probe and the specificity and immunogenicity of the reporter gene. The objective of the present study was to evaluate a new approach for reporter gene imaging based on cell surface expression of antibody fragments that can irreversibly bind to radiometal chelates. Methods: We developed a new reporter gene, designated 1,4,7,10-tetraazacyclodocecane-N,N′,N″,N‴-tetraacetic acid (DOTA) antibody reporter 1 (DAbR1), which consists of the single-chain Fv (scFv) fragment of the anti-Y-DOTA antibody 2D12.5/G54C fused to the human T cell CD4 transmembrane domain. The corresponding reporter probe is yttrium-(S)-2-(4- acrylamidobenzyl)-DOTA (*Y-AABD), a DOTA complex that binds irreversibly to a cysteine residue in the 2D12.5/G54C antibody. U-87 glioma cells were stably transfected with a DAbR1 expression vector. Binding of *Y-AABD to transfected and wild-type cells was studied in vitro and in vivo. Results: Flow cytometry revealed high expression of the DAbR1 protein on the cell surface of tumor cells. Uptake of 90Y-AABD in DAbR1-expressing human U-87 glioma xenografts was 6.2 (±1.3) percentage injected dose per gram (%ID/g) at 1 h and 4.9 (±0.62) %ID/g at 24 h after injection. The corresponding tumor-to-plasma ratios were 45:1 and 428:1, respectively. Uptake by U-87 tumors without the DAbR1 gene was 0.16 (±0.02) %ID/g at 1 h and 0.05 (±0.03) %ID/g at 24 h. PET images in mice with 86Y-AABD demonstrated intense uptake in DAbR1-positive tumors and low background activity in the liver. Conclusion: These findings indicate that cell surface expression of radiometal chelate binding antibodies such as 2D12.5/G54C is a promising strategy for reporter gene imaging.

Original languageEnglish (US)
Pages (from-to)1828-1835
Number of pages8
JournalJournal of Nuclear Medicine
Volume49
Issue number11
DOIs
StatePublished - Nov 1 2008

Fingerprint

Immunoglobulin Fragments
Reporter Genes
Antibodies
Glioma
Neoplasms
Cell Tracking
Immunoglobulin Variable Region
Yttrium
Single-Chain Antibodies
Heterografts
Genetic Therapy
Cysteine
Flow Cytometry
Membrane Proteins
T-Lymphocytes
Injections
Liver

Keywords

  • AABD
  • Noninvasive imaging
  • Reporter gene
  • Single-chain Fv antibody
  • Surface expression

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Wei, L. H., Olafsen, T., Radu, C., Hildebrandt, I. J., McCoy, M. R., Phelps, M. E., ... Weber, W. A. (2008). Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. Journal of Nuclear Medicine, 49(11), 1828-1835. https://doi.org/10.2967/jnumed.108.054452

Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. / Wei, Liu H.; Olafsen, Tove; Radu, Caius; Hildebrandt, Isabel J.; McCoy, Mark R.; Phelps, Michael E.; Meares, Claude; Wu, Anna M.; Czernin, Johannes; Weber, Wolfgang A.

In: Journal of Nuclear Medicine, Vol. 49, No. 11, 01.11.2008, p. 1828-1835.

Research output: Contribution to journalArticle

Wei, LH, Olafsen, T, Radu, C, Hildebrandt, IJ, McCoy, MR, Phelps, ME, Meares, C, Wu, AM, Czernin, J & Weber, WA 2008, 'Engineered antibody fragments with infinite affinity as reporter genes for PET imaging', Journal of Nuclear Medicine, vol. 49, no. 11, pp. 1828-1835. https://doi.org/10.2967/jnumed.108.054452
Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME et al. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. Journal of Nuclear Medicine. 2008 Nov 1;49(11):1828-1835. https://doi.org/10.2967/jnumed.108.054452
Wei, Liu H. ; Olafsen, Tove ; Radu, Caius ; Hildebrandt, Isabel J. ; McCoy, Mark R. ; Phelps, Michael E. ; Meares, Claude ; Wu, Anna M. ; Czernin, Johannes ; Weber, Wolfgang A. / Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. In: Journal of Nuclear Medicine. 2008 ; Vol. 49, No. 11. pp. 1828-1835.
@article{5203ff8ee0944ac1aa0d6e5a8c7edf49,
title = "Engineered antibody fragments with infinite affinity as reporter genes for PET imaging",
abstract = "Reporter gene imaging has great potential for many clinical applications including the tracking of transplanted cells and monitoring of gene therapy. However, currently available reporter gene-reporter probe combinations have significant limitations with the biodistribution of the reporter probe and the specificity and immunogenicity of the reporter gene. The objective of the present study was to evaluate a new approach for reporter gene imaging based on cell surface expression of antibody fragments that can irreversibly bind to radiometal chelates. Methods: We developed a new reporter gene, designated 1,4,7,10-tetraazacyclodocecane-N,N′,N″,N‴-tetraacetic acid (DOTA) antibody reporter 1 (DAbR1), which consists of the single-chain Fv (scFv) fragment of the anti-Y-DOTA antibody 2D12.5/G54C fused to the human T cell CD4 transmembrane domain. The corresponding reporter probe is yttrium-(S)-2-(4- acrylamidobenzyl)-DOTA (*Y-AABD), a DOTA complex that binds irreversibly to a cysteine residue in the 2D12.5/G54C antibody. U-87 glioma cells were stably transfected with a DAbR1 expression vector. Binding of *Y-AABD to transfected and wild-type cells was studied in vitro and in vivo. Results: Flow cytometry revealed high expression of the DAbR1 protein on the cell surface of tumor cells. Uptake of 90Y-AABD in DAbR1-expressing human U-87 glioma xenografts was 6.2 (±1.3) percentage injected dose per gram ({\%}ID/g) at 1 h and 4.9 (±0.62) {\%}ID/g at 24 h after injection. The corresponding tumor-to-plasma ratios were 45:1 and 428:1, respectively. Uptake by U-87 tumors without the DAbR1 gene was 0.16 (±0.02) {\%}ID/g at 1 h and 0.05 (±0.03) {\%}ID/g at 24 h. PET images in mice with 86Y-AABD demonstrated intense uptake in DAbR1-positive tumors and low background activity in the liver. Conclusion: These findings indicate that cell surface expression of radiometal chelate binding antibodies such as 2D12.5/G54C is a promising strategy for reporter gene imaging.",
keywords = "AABD, Noninvasive imaging, Reporter gene, Single-chain Fv antibody, Surface expression",
author = "Wei, {Liu H.} and Tove Olafsen and Caius Radu and Hildebrandt, {Isabel J.} and McCoy, {Mark R.} and Phelps, {Michael E.} and Claude Meares and Wu, {Anna M.} and Johannes Czernin and Weber, {Wolfgang A.}",
year = "2008",
month = "11",
day = "1",
doi = "10.2967/jnumed.108.054452",
language = "English (US)",
volume = "49",
pages = "1828--1835",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "11",

}

TY - JOUR

T1 - Engineered antibody fragments with infinite affinity as reporter genes for PET imaging

AU - Wei, Liu H.

AU - Olafsen, Tove

AU - Radu, Caius

AU - Hildebrandt, Isabel J.

AU - McCoy, Mark R.

AU - Phelps, Michael E.

AU - Meares, Claude

AU - Wu, Anna M.

AU - Czernin, Johannes

AU - Weber, Wolfgang A.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Reporter gene imaging has great potential for many clinical applications including the tracking of transplanted cells and monitoring of gene therapy. However, currently available reporter gene-reporter probe combinations have significant limitations with the biodistribution of the reporter probe and the specificity and immunogenicity of the reporter gene. The objective of the present study was to evaluate a new approach for reporter gene imaging based on cell surface expression of antibody fragments that can irreversibly bind to radiometal chelates. Methods: We developed a new reporter gene, designated 1,4,7,10-tetraazacyclodocecane-N,N′,N″,N‴-tetraacetic acid (DOTA) antibody reporter 1 (DAbR1), which consists of the single-chain Fv (scFv) fragment of the anti-Y-DOTA antibody 2D12.5/G54C fused to the human T cell CD4 transmembrane domain. The corresponding reporter probe is yttrium-(S)-2-(4- acrylamidobenzyl)-DOTA (*Y-AABD), a DOTA complex that binds irreversibly to a cysteine residue in the 2D12.5/G54C antibody. U-87 glioma cells were stably transfected with a DAbR1 expression vector. Binding of *Y-AABD to transfected and wild-type cells was studied in vitro and in vivo. Results: Flow cytometry revealed high expression of the DAbR1 protein on the cell surface of tumor cells. Uptake of 90Y-AABD in DAbR1-expressing human U-87 glioma xenografts was 6.2 (±1.3) percentage injected dose per gram (%ID/g) at 1 h and 4.9 (±0.62) %ID/g at 24 h after injection. The corresponding tumor-to-plasma ratios were 45:1 and 428:1, respectively. Uptake by U-87 tumors without the DAbR1 gene was 0.16 (±0.02) %ID/g at 1 h and 0.05 (±0.03) %ID/g at 24 h. PET images in mice with 86Y-AABD demonstrated intense uptake in DAbR1-positive tumors and low background activity in the liver. Conclusion: These findings indicate that cell surface expression of radiometal chelate binding antibodies such as 2D12.5/G54C is a promising strategy for reporter gene imaging.

AB - Reporter gene imaging has great potential for many clinical applications including the tracking of transplanted cells and monitoring of gene therapy. However, currently available reporter gene-reporter probe combinations have significant limitations with the biodistribution of the reporter probe and the specificity and immunogenicity of the reporter gene. The objective of the present study was to evaluate a new approach for reporter gene imaging based on cell surface expression of antibody fragments that can irreversibly bind to radiometal chelates. Methods: We developed a new reporter gene, designated 1,4,7,10-tetraazacyclodocecane-N,N′,N″,N‴-tetraacetic acid (DOTA) antibody reporter 1 (DAbR1), which consists of the single-chain Fv (scFv) fragment of the anti-Y-DOTA antibody 2D12.5/G54C fused to the human T cell CD4 transmembrane domain. The corresponding reporter probe is yttrium-(S)-2-(4- acrylamidobenzyl)-DOTA (*Y-AABD), a DOTA complex that binds irreversibly to a cysteine residue in the 2D12.5/G54C antibody. U-87 glioma cells were stably transfected with a DAbR1 expression vector. Binding of *Y-AABD to transfected and wild-type cells was studied in vitro and in vivo. Results: Flow cytometry revealed high expression of the DAbR1 protein on the cell surface of tumor cells. Uptake of 90Y-AABD in DAbR1-expressing human U-87 glioma xenografts was 6.2 (±1.3) percentage injected dose per gram (%ID/g) at 1 h and 4.9 (±0.62) %ID/g at 24 h after injection. The corresponding tumor-to-plasma ratios were 45:1 and 428:1, respectively. Uptake by U-87 tumors without the DAbR1 gene was 0.16 (±0.02) %ID/g at 1 h and 0.05 (±0.03) %ID/g at 24 h. PET images in mice with 86Y-AABD demonstrated intense uptake in DAbR1-positive tumors and low background activity in the liver. Conclusion: These findings indicate that cell surface expression of radiometal chelate binding antibodies such as 2D12.5/G54C is a promising strategy for reporter gene imaging.

KW - AABD

KW - Noninvasive imaging

KW - Reporter gene

KW - Single-chain Fv antibody

KW - Surface expression

UR - http://www.scopus.com/inward/record.url?scp=57349114294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349114294&partnerID=8YFLogxK

U2 - 10.2967/jnumed.108.054452

DO - 10.2967/jnumed.108.054452

M3 - Article

C2 - 18927335

AN - SCOPUS:57349114294

VL - 49

SP - 1828

EP - 1835

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 11

ER -